Poster-Disease-modifying Therapy
October 25, 2021
Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening Early 3 Months Post Approval Data
Background: Superior efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. Objectives: The social media...
Poster-Disease-modifying Therapy
October 25, 2021
Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study
Background: Siponimod is a selective S1P receptor (S1P1 and S1P5) modulator, approved in the USA for treatment of relapsing forms of MS,...
Poster-Disease-modifying Therapy
October 25, 2021
Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World
Background: Siponimod was approved in the United States (US) in March 2019 for patients with relapsing forms of Multiple Sclerosis (MS)....
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years
Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...
Poster-Disease-modifying Therapy
October 25, 2021
Real-World Cost of Care, Treatment Completion and Site of Care Cost for Patients with Multiple Sclerosis Initiating Infused Disease-Modifying Therapies
Background: Expenditures for intravenous (IV) disease-modifying therapies (DMTs) for multiple sclerosis (MS) include costs beyond wholesale...
Poster-Disease-modifying Therapy
October 25, 2021
Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab
Background: A global pandemic of COVID-19 has resulted in over 78 million cases as of 23 December 2020. Risks of COVID-19 in people with...
October 25, 2021
Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire
Background: The validated physician-completed MSProDiscussTM tool facilitates physician-patient interaction in evaluating early signs of...
Platform-Disease Modifying Therapies
October 25, 2021
Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design
Background: Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of adults with relapsing multiple...
October 25, 2021
Health-Related Quality of Life across the Lifespan in Persons with Multiple Sclerosis and Healthy Controls
Background: Health-related quality of life (HRQOL) is reduced in persons with multiple sclerosis (MS) compared with the general population,...